Cambodia vs Cuba: HIV/AIDS deaths averted by antiretroviral therapy
Cambodia
1,355 deaths
in 2024
Cuba
1,468 deaths
in 2024
Cambodia rank
68th
Cuba rank
65th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Cambodia
- Cuba
How they compare
Cuba currently reports 1,468 deaths against 1,355 deaths in Cambodia, a difference of 113 deaths.
That makes Cuba's figure about 1.1 times Cambodia's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Cuba ahead.
Cambodia ranks 68th and Cuba ranks 65th of 157 countries.
Cambodia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cambodia | Cuba | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 1,701 deaths | 292.14 deaths | 1,409 deaths | Cambodia |
| 2010s | 3,140 deaths | 1,136 deaths | 2,004 deaths | Cambodia |
| 2020s | 1,580 deaths | 1,525 deaths | 55.55 deaths | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Cambodia or Cuba?
- Cuba, at 1,468 deaths against 1,355 deaths in Cambodia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Cambodia and Cuba?
- 113 deaths, with Cuba ahead.
- How many years of comparable data are there for Cambodia and Cuba?
- 35 years are reported by both, from 1990 to 2024.
- How do Cambodia and Cuba rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Cambodia ranks 68th and Cuba ranks 65th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.